Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
37.32
+0.16 (0.43%)
Sep 15, 2025, 10:31 AM EDT - Market open
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $193.00K in the quarter ending June 30, 2025, a decrease of -89.64%. This brings the company's revenue in the last twelve months to $4.85M, up 17.87% year-over-year. In the year 2024, Dianthus Therapeutics had annual revenue of $6.24M with 120.63% growth.
Revenue (ttm)
$4.85M
Revenue Growth
+17.87%
P/S Ratio
270.39
Revenue / Employee
$62,231
Employees
78
Market Cap
1.20B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
Dec 31, 2021 | 1.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDNTH News
- 3 days ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 days ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering - GlobeNewsWire
- 6 days ago - Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call - Seeking Alpha
- 6 days ago - Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering - GlobeNewsWire
- 7 days ago - Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - GlobeNewsWire
- 7 days ago - Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire